Please login to the form below

Not currently logged in
Email:
Password:

cHL

This page shows the latest cHL news and features for those working in and with pharma, biotech and healthcare.

China’s BeiGene takes PD-1 antibody into pivotal trials

China’s BeiGene takes PD-1 antibody into pivotal trials

The single-arm trial enrolled 70 cHL patients who had failed autologous stem cell transplantation (ASCT) – a primary treatment for the cancer – or were ineligible for the procedure.

Latest news

  • Merck suspends two Keytruda trials after patient deaths Merck suspends two Keytruda trials after patient deaths

    Earlier this year Keytruda was approved for classical Hodgkin lymphoma (cHL) - its first non-solid tumour indication - and expanding into blood cancers is a key target for Merck.

  • Keytruda and Opdivo backed for new uses in Europe Keytruda and Opdivo backed for new uses in Europe

    cHL), shortly after the FDA cleared the drug for the same blood cancer in the US. ... BMS' Opdivo (nivolumab) - which is already approved in the EU for cHL - was given the nod for the treatment for adults with squamous cell cancer of the head and neck

  • Keytruda claims first blood cancer OK from FDA Keytruda claims first blood cancer OK from FDA

    Merck &Co has won FDA clearance for its PD-1 inhibitor Keytruda in classical Hodgkin lymphoma (cHL), the first green light for the drug in a haematological cancer. ... The US regulator gave a conditional approval to Keytruda (pembrolizumab) for cHL

  • Opdivo gets green light for Hodgkin lymphoma in Europe Opdivo gets green light for Hodgkin lymphoma in Europe

    Less common than non-Hodgkin's lymphoma, cHL affects around 12, 200 people in the EU every year, often being diagnosed in early adulthood. ... BMS says the drug is still showing robust growth in other indications such as melanoma, renal cancer and cHL.

  • BMS wins early UK access for Opdivo in Hodgkin’s lymphoma BMS wins early UK access for Opdivo in Hodgkin’s lymphoma

    The Medicines Healthcare Products and Regulatory Agency (MHRA) approved Opdivo for early access as a monotherapy for the treatment of adults with relapsed or refractory classical Hodgkin lymphoma (cHL) who have ... In a recent phase II trial, the

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics